跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
昕越 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Inebilizumab Injection
Approved
生物制品
Inebilizumab Injection
HORIZON THERAPEUTICS IRELAND DAC
🇨🇳 National Medical Products Administration
Approval Date
Mar 8, 2022
Approval ID
8Elyvaor186
Company
HORIZON THERAPEUTICS IRELAND DAC
Type
生物制品
Approval Details
Approval Id
8Elyvaor186
Approval Number
国药准字SJ20220007
Generic Name
伊奈利珠单抗注射液
Generic Name En
Inebilizumab Injection
Trade Name
昕越
Drug Type
生物制品
Dosage Form
注射剂
Strength
100mg(10mL)/小瓶
Reg Date
2022-03-08
Expired Date
2027-03-07
Company Name
HORIZON THERAPEUTICS IRELAND DAC
Production Company Name
AstraZeneca Nijmegen B.V.
Company Detail Path
/organization/horizon-therapeutics-ireland-dac
Production Company Detail Path
/organization/astrazeneca-nijmegen-b-v
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Mar 8, 2022
Approval ID
8Elyvaor186
Type
生物制品
Back to NMPA Approvals